SCM
SUPN icon

Soleus Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Soleus Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-258,100
Closed -$7.46M – 90
2022
Q2 		$7.46M Buy
258,100
+7,100
+3% +$203K 1.16% 32
2022
Q1 		$8.11M Buy
+251,000
New +$7.7M 1.05% 30

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Soleus Capital Management's SUPN Position: Q3 2022 in Review

Soleus Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2022, closing a stake of 258,100 shares — an estimated $7.46M sold.

Soleus Capital Management first reported a position in SUPN in Q1 2022 and held it in 2 quarters. The position peaked at $8.11M in Q1 2022. 244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

  • Soleus Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Soleus Capital Management sold 258,100 Supernus Pharmaceuticals shares in Q3 2022, an estimated $7.46M.
  • Soleus Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Soleus Capital Management's Supernus Pharmaceuticals position peaked at $8.11M in Q1 2022.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.